Drug research

Apitegromab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as SRK-015

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or RisdiplamNCT05156320	Scholar Rock, Inc.	Phase 3	Completed	2024-12-18Actual
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseNCT06445075	Scholar Rock, Inc.	Phase 2	Completed	2025-03-04Actual
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular AtrophyNCT07047144	Scholar Rock, Inc.	Phase 2	Recruiting	2028-11Estimated
Phase 2 Study Evaluating Apitegromab for the Treatment of FSHDNCT07435129	Scholar Rock, Inc.	Phase 2	Recruiting	2028-06Estimated
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of ApitegromabNCT05626855	Scholar Rock, Inc.	Phase 3	Active not recruiting	2026-11-01Estimated

Scholar Rock, Inc.CompletedPrimary completion: 2024-12-18 · Actual

Trial details

Scholar Rock, Inc.CompletedPrimary completion: 2025-03-04 · Actual

Trial details

Scholar Rock, Inc.RecruitingPrimary completion: 2028-11 · Estimated

Trial details

Scholar Rock, Inc.RecruitingPrimary completion: 2028-06 · Estimated

Trial details

Scholar Rock, Inc.Active not recruitingPrimary completion: 2026-11-01 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.